Summary
Zoetis Inc.'s 2016 10-K report highlights a strong year of growth and strategic execution. The company, a global leader in animal health, reported total revenue of $4.89 billion, a 3% increase year-over-year, driven by operational revenue growth of 5%. This growth was primarily fueled by key product performance, including Apoquel, and contributions from recent acquisitions like Pharmaq. The company continues to balance investment in new product development with optimizing its existing portfolio and operational efficiency, as evidenced by its ongoing operational efficiency program. Zoetis operates in two key segments: the United States and International, with each contributing nearly half of the total revenue, showcasing a well-diversified geographic footprint. Financially, Zoetis demonstrated solid performance with net income attributable to Zoetis of $821 million, a significant increase from the prior year, supported by improved cost management and operational leverage. The company also managed its debt effectively and continued its commitment to shareholder returns through dividends and share repurchases. Key risks identified include regulatory changes regarding antibiotic use in livestock, increased competition, and global economic conditions, all of which the company is actively managing.
Financial Highlights
54 data points| Revenue | $4.89B |
| Cost of Revenue | $1.67B |
| Gross Profit | $3.22B |
| SG&A Expenses | $1.36B |
| Interest Expense | $166.00M |
| Net Income | $819.00M |
| EPS (Basic) | $1.66 |
| EPS (Diluted) | $1.65 |
| Shares Outstanding (Basic) | 495.71M |
| Shares Outstanding (Diluted) | 498.23M |
Key Highlights
- 1Zoetis reported total revenue of $4.89 billion for fiscal year 2016, an increase of 3% from 2015, driven by strong operational revenue growth of 5%.
- 2The company's diverse product portfolio serves both livestock (59% of revenue) and companion animals (40% of revenue), with key product lines like ceftiofur and Apoquel driving significant revenue.
- 3Zoetis maintains a balanced geographic presence, with the United States (50% of revenue) and International markets (49% of revenue) contributing substantially to its top line.
- 4Net income attributable to Zoetis was $821 million, a significant increase from $339 million in 2015, reflecting improved profitability and operational efficiency.
- 5The company continued to invest in Research and Development, with R&D expenses of $376 million, focusing on both new product innovation and product lifecycle management.
- 6Zoetis is actively pursuing an operational efficiency program, which includes streamlining its product portfolio and optimizing its manufacturing and supply chain.
- 7The company is committed to shareholder returns, evidenced by consistent dividend payments and significant share repurchase activity authorized in December 2016.